标题
Reprogramming of the MicroRNA Transcriptome Mediates Resistance to Rapamycin
作者
关键词
-
出版物
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 288, Issue 9, Pages 6034-6044
出版商
American Society for Biochemistry & Molecular Biology (ASBMB)
发表日期
2013-01-09
DOI
10.1074/jbc.m112.416446
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Rapamycin Resistance Is Linked to Defective Regulation of Skp2
- (2012) H. Totary-Jain et al. CANCER RESEARCH
- Cooperative control of tumor suppressor genes by a network of oncogenic microRNAs
- (2011) Konstantinos J. Mavrakis et al. CELL CYCLE
- PI3K/AKT signaling determines a dynamic switch between distinct KSRP functions favoring skeletal myogenesis
- (2011) P Briata et al. CELL DEATH AND DIFFERENTIATION
- MicroRNA let-7c Suppresses Androgen Receptor Expression and Activity via Regulation of Myc Expression in Prostate Cancer Cells
- (2011) Nagalakshmi Nadiminty et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Transcriptome-wide Identification of RNA-Binding Protein and MicroRNA Target Sites by PAR-CLIP
- (2010) Markus Hafner et al. CELL
- Thelet-7microRNA reduces tumor growth in mouse models of lung cancer
- (2010) Aurora Esquela-Kerscher et al. CELL CYCLE
- The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF-β Pathway in Neuroblastoma
- (2010) Pieter Mestdagh et al. MOLECULAR CELL
- Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein
- (2010) J Xiong et al. ONCOGENE
- Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy
- (2009) Ryan J.O. Dowling et al. BIODRUGS
- MicroRNAs: new players in acute myeloid leukaemia
- (2009) V Havelange et al. BRITISH JOURNAL OF CANCER
- MYC Activity Mitigates Response to Rapamycin in Prostate Cancer through Eukaryotic Initiation Factor 4E-Binding Protein 1-Mediated Inhibition of Autophagy
- (2009) B. S. Balakumaran et al. CANCER RESEARCH
- mTOR inhibitors for hepatocellular cancer: a forward-moving target
- (2009) Gerhard Treiber Expert Review of Anticancer Therapy
- mTOR in renal cell cancer: modulator of tumor biology and therapeutic target
- (2009) Piotr J Wysocki EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- miR-19 is a key oncogenic component of mir-17-92
- (2009) V. Olive et al. GENES & DEVELOPMENT
- Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
- (2009) Susan L. Ellard et al. JOURNAL OF CLINICAL ONCOLOGY
- Diagnostic Assay Based on hsa-miR-205 Expression Distinguishes Squamous From Nonsquamous Non–Small-Cell Lung Carcinoma
- (2009) Danit Lebanony et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition
- (2009) M. Breuleux et al. MOLECULAR CANCER THERAPEUTICS
- The RNA-binding protein KSRP promotes the biogenesis of a subset of microRNAs
- (2009) Michele Trabucchi et al. NATURE
- Everolimus
- (2009) Michael B. Atkins et al. NATURE REVIEWS DRUG DISCOVERY
- Role of miR-143 targeting KRAS in colorectal tumorigenesis
- (2009) X Chen et al. ONCOGENE
- Progress in the treatment of neuroendocrine tumors
- (2009) Jennifer A. Chan et al. Current Oncology Reports
- MicroRNAs as biomarkers and therapeutic drugs in human cancer
- (2008) M. Osaki et al. BIOMARKERS
- Microarray background correction: maximum likelihood estimation for the normal-exponential convolution
- (2008) J. D. Silver et al. BIOSTATISTICS
- Deforolimus (AP23573) a novel mTOR inhibitor in clinical development
- (2008) Monica Mita et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The Potential Role of mTOR Inhibitors in Non-Small Cell Lung Cancer
- (2008) C. Gridelli et al. ONCOLOGIST
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now